ArticleslgStudy

chemistry

Tabernanthalog

Tabernanthalog is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Tabernanthalog rather than just read about it. In short: Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure. It was developed by David E.

Tabernanthalog — main illustration
Tabernanthalog — illustration

Key takeaways

  • Tabernanthalog belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Tabernanthalog to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Tabernanthalog from memory before moving on to harder problems.

Reference excerpt

Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure. It was developed by David E. Olson and colleagues at the University of California, Davis. The drug is being developed by Delix Therapeutics as a potential pharmaceutical drug for treatment of neuropsychiatric disorders. However, as of January 2026, tabernanthalog has still yet to enter clinical trials.

Use and effects There have been informal anecdotal reports of the effects of tabernanthalog.

Interactions

Pharmacology

Pharmacodynamics

Tabernanthalog is a non-selective and non-psychedelic serotonin receptor modulator, including acting as an agonist of the serotonin 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2C, and 5-HT6 receptors and as an agonist or antagonist of the serotonin 5-HT2B receptor. It also shows significant binding to the serotonin transporter (SERT) (acting as a serotonin reuptake inhibitor), the α2A-adrenergic receptor, and monoamine oxidase A (MAO-A). In contrast to iboga alkaloids like ibogaine and noribogaine, tabernanthalog showed negligible interactions with opioid receptors, the NMDA receptor, and certain nicotinic acetylcholine receptors. However, in subsequent research, it weakly inhibited certain nicotinic acetylcholine receptors, as well as, to a much lesser extent, the GABAA receptor. Tabernanthalog was found to be 100-fold less potent at the hERG antitarget compared to ibogaine, and hence is thought to have a much lower potential for cardiotoxicity. Tabernanthalog did not produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents, and hence appears to be non-hallucinogenic. However, it was found to promote structural neuroplasticity (i.e., to act as a psychoplastogen), reduce drug-seeking behavior, and produce antidepressant-like effects. It has also been shown that it reduces motivation for heroin and alcohol in rodents.

History Tabernanthalog was first described in the scientific literature by David E. Olson and colleagues at the University of California, Davis in January 2021.

Society and culture

Grey market use Tabernanthalog has been known to be sold online by research chemical vendors for purposes such as "nootropic" use.

Legal status

Canada Tabernanthalog is not a controlled substance in Canada.

United States Tabernanthalog is not an explicitly controlled substance in the United States.

Research Tabernanthalog is under development for the treatment of central nervous system disorders (CNS disorders). It is being developed by Delix Therapeutics. As of May 2025, no recent development has been reported. It had reached the preclinical research stage of development. A phase 1 clinical trial was being planned for the first half of 2023. Delix Therapeutics also partnered with National Institute on Drug Abuse (NIDA) to evaluate tabernanthalog for the treatment of substance-related disorders in December 2021. As of January 2026, tabernanthalog has still yet to enter clinical trials.

See also Ibogalog Non-hallucinogenic 5-HT2A receptor agonist List of investigational hallucinogens and entactogens Tabernanthine Catharanthalog DLX-159 Ibogainalog Ibogaminalog (DM-506) Noribogainalog PNU-22394

References

External links Tabernanthalog - Isomer Design

Illustrations

Tabernanthalog illustration
Tabernanthalog illustration

Worked examples

Example 1 — a first encounter with Tabernanthalog

Start with the simplest possible case. Write down what Tabernanthalog claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Tabernanthalog before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Tabernanthalog ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Tabernanthalog

In research
Tabernanthalog appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Tabernanthalog in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Tabernanthalog is common in secondary-school and first-year university syllabi. It links to neighbouring topics 5-HT1B agonists, 5-HT1F agonists, 5-HT2B agonists, so understanding it makes those chapters shorter.
In everyday life
Look for Tabernanthalog outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Tabernanthalog” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Tabernanthalog in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Tabernanthalog means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Tabernanthalog out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Tabernanthalog in simple terms?

Tabernanthalog (TBG; developmental code name DLX-007) is a non-selective serotonin receptor modulator and putatively non-psychedelic psychoplastogen of the ibogalog group related to the iboga alkaloid tabernanthine but with a simplified chemical structure. It was developed by David E.

Why does Tabernanthalog matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Tabernanthalog?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Tabernanthalog.

Tags

  • 5-HT1B agonists
  • 5-HT1F agonists
  • 5-HT2B agonists
  • 5-HT2B antagonists
  • 5-HT2C agonists
  • 5-HT6 agonists
  • Adrenergic receptor modulators
  • Drugs not assigned an ATC code
  • Experimental non-hallucinogens
  • Ibogalogs
  • Methoxy compounds
  • N,N-Dialkyltryptamines

Keep exploring